

## Special Issue

# Personalized Medicine of Coronary Artery Disease

### Message from the Guest Editor

Personalized medicine is developing fast, and new data are emerging in huge amounts. This might enable the right risk assessment, diagnosis, prevention, and therapy specifically tailored to the unique characteristics of the individual, thus enhancing the quality of life as well as public health. Therefore, the aim of this Special Issue is to present recent developments in personalized medicine and coronary artery disease. We invite authors to submit original clinical studies, reviews, meta-analyses, as well as case reports focused on the individualization of the prevention, diagnosis, and treatment of coronary artery disease, including myocardial infarction. We are soliciting not only genetic studies, but all papers on the broadly understood personalized medicine, including papers on novel drugs, medical devices, or approaches dedicated to special subsets of patients.

---

### Guest Editor

Dr. Jacek Bil

Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical, Hospital of the Ministry of Interior and Administration, Woloska 137 Street, 02-507 Warsaw, Poland

---

### Deadline for manuscript submissions

closed (28 February 2022)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/51020](https://mdpi.com/si/51020)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).